SCHEMBL3755193

SCHEMBL3755193

O=S(=O)(O)c1cccc2c(Nc3ccccc3)cccc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 2/20 0.65
FABP4 P15090 1/20 0.65
CCNA2 P20248 1/20 0.65
CDK2 P24941 1/20 0.65
MAPK14 Q16539 1/20 0.65
SNCA P37840 2/20 0.64
CHAT P28329 1/20 0.64
GAA P10253 3/20 0.63
MEN1 O00255 3/20 0.63
KMT2A Q03164 3/20 0.63
KDM4E B2RXH2 2/20 0.63
MAPT P10636 2/20 0.63
RECQL P46063 2/20 0.63
TDP1 Q9NUW8 2/20 0.63
GLA P06280 1/20 0.63
NR4A1 P22736 1/20 0.63
CDC25B P30305 4/20 0.53
ALDH1A1 P00352 3/20 0.53
HPGD P15428 2/20 0.53
ATM Q13315 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30924525 1.00 TTR (0.65) TTRFABP4CCNA2CDK2MAPK14
SCHEMBL6345196 0.92 SNCA (0.61) TTRFABP4CCNA2CDK2MAPK14
SCHEMBL22501407 0.86 SNCA (0.63) TTRFABP4CCNA2CDK2MAPK14
SCHEMBL27480237 0.84 SNCA (0.62) TTRFABP4CCNA2CDK2MAPK14
SCHEMBL6264332 0.84 FABP4 (0.70) TTRFABP4CCNA2CDK2MAPK14
Ammonia Solution, Strong SCHEMBL1556275 0.82 NR4A1 (0.71) TTRFABP4CCNA2CDK2MAPK14
SCHEMBL29430564 0.80 NR4A1 (0.68) TTRFABP4CCNA2CDK2MAPK14
SCHEMBL18324651 0.80 SNCA (0.71) TTRFABP4CCNA2CDK2MAPK14
SCHEMBL6404861 0.80 MEN1 (1.00) FABP4GAAMEN1KMT2AKDM4E
Sulfuric Acid SCHEMBL4742846 0.79 CDC25B (0.79) TTRFABP4CCNA2CDK2MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1272156-B1 USE OF ALCOHOL DEHYDROGENASE INHIBITORS FOR COSMETIC TREATMENT OF KERATINOUS MATERIALS OREAL (FR) 2006-05-31 EP claimed
US-20030138390-A1 Use of alcohol dehydrogenase inhibitors for cosmetic treatment of keratinous materials L'OREAL (FR) 2003-07-24 US claimed
CN-111356764-B Compositions and methods for reducing serum cholesterol and PCSK9 卡斯西部储备大学 2024-05-24 CN disclosed
US-11931339-B2 Compositions and methods for treating tissue injury CASE WESTERN RESERVE UNIVERSITY (US) 2024-03-19 US disclosed
US-20230190710-A1 COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 UNIV CASE WESTERN RESERVE (US) 2023-06-22 US disclosed
US-20230093056-A1 COMPOSITIONS AND METHODS OF MODULATING S-NITROSYLATION UNIV CASE WESTERN RESERVE (US) 2023-03-23 US disclosed
US-20230054339-A1 COMPOSITIONS AND METHODS OF MODULATING S-NITROSYLATION UNIV CASE WESTERN RESERVE (US) 2023-02-23 US disclosed
US-11576900-B2 Compositions and methods of reducing serum cholesterol and PCSK9 CASE WESTERN RESERVE UNIVERSITY (US) 2023-02-14 US disclosed
US-20230024914-A1 METHODS OF TREATING RESPIRATORY DISORDERS UNIV CASE WESTERN RESERVE (US) 2023-01-26 US disclosed
US-11559498-B2 Compositions and methods for in vivo lung and blood SNO repletion UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER (US) 2023-01-24 US disclosed
US-11389430-B2 Methods of treating respiratory disorders CASE WESTERN RESERVE UNIVERSITY (US) 2022-07-19 US disclosed
CN-102549460-A Coloring composition and color filter TOYO INK SC HOLDINGS CO LTD 2012-07-04 CN disclosed
US-20110195249-A1 ADHESIVE COMPOSITION AND OPTICAL MEMBER Wuxi Hengxin Optoelectronic Materials Co., Ltd. (CN) 2011-08-11 US disclosed
US-20100305078-A1 METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES VIAMET PHARMACEUTICALS, INC. (US) 2010-12-02 US disclosed
US-7786224-B2 Liquid composition of alicyclic diepoxide, curing agent and/or curing accelerator DAICEL CHEMICAL INDUSTRIES, LTD (JP) 2010-08-31 US disclosed
US-20090281275-A1 Curable resin compositions and interlayer dielectric films DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2009-11-12 US disclosed
EP-2086546-A2 METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES Viamet Pharmaceuticals, Inc. (US) 2009-08-12 EP disclosed
WO-2008064311-A2 METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES VIAMET PHARMACEUTICALS, INC. (US) 2008-05-29 WO disclosed
US-20050089930-A1 Polypeptide fingerprinting methods TARGET DISCOVERY, INC. (US) 2005-04-28 US disclosed
US-20030138390-A1 Use of alcohol dehydrogenase inhibitors for cosmetic treatment of keratinous materials L'OREAL (FR) 2003-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230093056-A1 COMPOSITIONS AND METHODS OF MODULATING S-NITROSYLATION AKR1A1, AKR1B1, AKR1C2 TTR 1233/4885FABP4 2160/4885CCNA2 4420/4885
US-11576900-B2 Compositions and methods of reducing serum cholesterol and PCSK9 PCSK9, HMGCR, PCSK7 TTR 502/4885FABP4 881/4885CCNA2 4677/4885
US-20230054339-A1 COMPOSITIONS AND METHODS OF MODULATING S-NITROSYLATION AKR1B1, AKR1C2, AKR1A1 TTR 1433/4885FABP4 1174/4885CCNA2 4233/4885
US-20230024914-A1 METHODS OF TREATING RESPIRATORY DISORDERS GSR, GSS, TXNRD2 TTR 2609/4885FABP4 2831/4885CCNA2 4479/4885
US-11389430-B2 Methods of treating respiratory disorders GSR, GSS, TXNRD2 TTR 2609/4885FABP4 2831/4885CCNA2 4479/4885
US-20230190710-A1 COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 PCSK9, HMGCR, PCSK7 TTR 502/4885FABP4 881/4885CCNA2 4677/4885
US-11931339-B2 Compositions and methods for treating tissue injury PDK4, AK1, PDK1 TTR 721/4885FABP4 120/4885CCNA2 3768/4885
US-20100305078-A1 METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES NQO1, SOD1, MDH2 TTR 1519/4885FABP4 3504/4885CCNA2 4272/4885
US-11559498-B2 Compositions and methods for in vivo lung and blood SNO repletion GSR, GSS, HMOX1 TTR 500/4885FABP4 1964/4885CCNA2 4093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.